Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Secukinumab in MSS CRC
NCT04298320Phase 2Unknown
- Start
- Mar 2020
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, secukinumab in colorectal cancer (CRC). Status: unknown.
02
Drugs
camrelizumabsecukinumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04298320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298320.